MSF doctor Dr. Maham Khalid is examining four-year-old Ahmad during a consultation at the MSF-supported Programmatic Management of Drug-Resistant Tuberculosis (PMDT) site in Gujranwala, Punjab.

Photo Credit: Gul Nayab

Press release |

24 March 2026

MSF demands sustained investments and political will to end neglect of children with tuberculosis

1.2 million children have TB worldwide, but nearly half miss diagnosis and treatment

TUBERCULOSIS

Read more

Photo Credit: Gul Nayab

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Issue brief |

09 April 2026

AfricaKenyaRwandaSouth Africa

Shifting Global Health R&D Funding: Opportunities in a Changing Landscape

Press release |

30 March 2026

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.

Feature story |

27 March 2026

A mother’s journey: Caring for her children with drug-resistant TB

Issue brief |

26 March 2026

EthiopiaNigeriaSouth Sudan

Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights

Interview |

24 March 2026

How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience

Statement |

20 March 2026

MSF statement at IGWG6

Press release |

19 March 2026

MSF calls on EU to unlock progress in final Pandemic Agreement talks

Letter |

16 March 2026

Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all

Press release |

05 March 2026

DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance

Technical brief |

09 February 2026

Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System

Events |

06 February 2026

MSF statements at WHO Executive Board 158th session

Maria Atonio, 43-years-old farmer from Macomia, returns home after visiting MSF’s Clinic in Nanga to receive ART treatment and to have a medical appointment with MSF’s clinical officer to monitor her health.

Photo credit: MSF/Martim Gray Pereira

Press release |

19 March 2026

MSF calls on EU to unlock progress in final Pandemic Agreement talks

EU must guarantee access to medical tools for communities sharing pathogens and data

PANDEMIC PREPAREDNESS RESEARCH AND DEVELOPMENT

Read more

Photo credit: MSF/Martim Gray Pereira

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Issue brief |

09 April 2026

AfricaKenyaRwandaSouth Africa

Shifting Global Health R&D Funding: Opportunities in a Changing Landscape

Press release |

30 March 2026

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.

Feature story |

27 March 2026

A mother’s journey: Caring for her children with drug-resistant TB

Issue brief |

26 March 2026

EthiopiaNigeriaSouth Sudan

Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights

Press release |

24 March 2026

MSF demands sustained investments and political will to end neglect of children with tuberculosis

Interview |

24 March 2026

How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience

Statement |

20 March 2026

MSF statement at IGWG6

Letter |

16 March 2026

Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all

Press release |

05 March 2026

DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance

Technical brief |

09 February 2026

Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System

Events |

06 February 2026

MSF statements at WHO Executive Board 158th session

MSF bio lab at MSF’s Aden hospital controls and treats the anti-resistant infected cases. Aden-The Bio lab project was launched as part of the medical lab at MSF Aden hospital southern Yemen, on January 2017.

Photograph by Ehab Zawati/MSF

Technical brief |

09 February 2026

Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System

MSF recommendations on WHO Pathogen Access and Benefit-Sharing (PABS) systems

PANDEMIC PREPAREDNESS

Read more

Photograph by Ehab Zawati/MSF

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Issue brief |

09 April 2026

AfricaKenyaRwandaSouth Africa

Shifting Global Health R&D Funding: Opportunities in a Changing Landscape

Press release |

30 March 2026

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.

Feature story |

27 March 2026

A mother’s journey: Caring for her children with drug-resistant TB

Issue brief |

26 March 2026

EthiopiaNigeriaSouth Sudan

Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights

Press release |

24 March 2026

MSF demands sustained investments and political will to end neglect of children with tuberculosis

Interview |

24 March 2026

How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience

Statement |

20 March 2026

MSF statement at IGWG6

Press release |

19 March 2026

MSF calls on EU to unlock progress in final Pandemic Agreement talks

Letter |

16 March 2026

Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all

Press release |

05 March 2026

DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance

Events |

06 February 2026

MSF statements at WHO Executive Board 158th session

Every three minutes, a child dies of tuberculosis (TB), even though treatment is available. In children, under-diagnosis is a major obstacle to effective treatment. New WHO recommendations, including treatment decision algorithms, could change all that.

Photo Credit: Stuart Tibaweswa

Press release |

18 November 2025

MSF findings show WHO algorithms could double the number of children diagnosed and treated for TB

Governments must act now to ensure no child is left behind in the fight against this deadly disease

TUBERCULOSIS

Read more

Photo Credit: Stuart Tibaweswa

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Issue brief |

09 April 2026

AfricaKenyaRwandaSouth Africa

Shifting Global Health R&D Funding: Opportunities in a Changing Landscape

Press release |

30 March 2026

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.

Feature story |

27 March 2026

A mother’s journey: Caring for her children with drug-resistant TB

Issue brief |

26 March 2026

EthiopiaNigeriaSouth Sudan

Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights

Press release |

24 March 2026

MSF demands sustained investments and political will to end neglect of children with tuberculosis

Interview |

24 March 2026

How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience

Statement |

20 March 2026

MSF statement at IGWG6

Press release |

19 March 2026

MSF calls on EU to unlock progress in final Pandemic Agreement talks

Letter |

16 March 2026

Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all

Press release |

05 March 2026

DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance

Technical brief |

09 February 2026

Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System

Latest News

Statement |

24 January 2018

Intellectual property and trade Research and development

142nd WHO EB Agenda item 3.7 - Global strategy and plan of action on public health, innovation and intellectual property

Statement |

24 January 2018

Vaccines

142nd WHO EB Agenda item 3.6 - Addressing the global shortage of, and access to, medicines and vaccines

Events |

24 January 2018

Vaccines

MSF briefings and interventions at WHO Executive Board 142nd session

Issue brief

Issue brief |

24 January 2018

Tropical & neglected diseases

142nd WHO EB Agenda item 4.1 - Global snakebite burden

Nicsonne Dadjam, 13, is treated at Paoua Hospital, northwestern Central African Republic, supported by MSF. He was bitten by a snake while working in the fields in his village, 2 hours by motorbike from Paoua. His older brother is checking his temperature, 2018.

Photograph by Alexis Huguet

Feature story |

18 January 2018

Tropical & neglected diseases

People affected by fatal snakebites in sub-Saharan Africa are in desperate need of affordable, quality antivenoms

Issue brief

Issue brief |

01 January 2018

Vaccines

142nd WHO EB Agenda item 6.2 - Global vaccine action plan

Wishlist 2018 banner

Photograph by MSF

Feature story |

01 January 2018

Our wishlist for 2018

3 min

Photograph by Siddharth Singh

Photograph by Siddharth Singh

IP RCEP protest in India.

Press release |

18 December 2017

China

MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices

AC20 Lives over profit video

Video

Lives Over Profit: a Patient, a Doctor and a Lawyer Take Action

Read more

100 years of insulin

Video |

14 April 2021

100 years of insulin

Read more

A Snapshot of the Access Campaign in 2017

Video

A Snapshot of the Access Campaign

Read more

Video thumbnail

Lives Over Profit: a Patient, a Doctor and a Lawyer Take Action

Video thumbnail

100 years of insulin

Video thumbnail

A Snapshot of the Access Campaign

Our work

Drug-resistant infections

Tropical & neglected diseases

Patents & intellectual property

Research & development